<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20445" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Diabetic Nephropathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Varghese</surname>
            <given-names>Ron T.</given-names>
          </name>
          <aff>White River Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jialal</surname>
            <given-names>Ishwarlal</given-names>
          </name>
          <aff>VA MEDICAL CENTER, MATHER , CA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ron Varghese declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ishwarlal Jialal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20445.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Diabetic kidney disease (DKD) is the main cause of end-stage kidney disease (ESKD) in developed countries, including the United States. It is considered a microvascular complication and occurs in both diabetes mellitus type 1 (T1DM) and diabetes mellitus type 2 (T2DM). Reliable tests for diagnosis and monitoring include urine albuminuria and the estimated GFR (eGFR). Optimizing glycemia and good blood pressure control are pivotal in halting the progression of DKD. This activity reviews the cause and pathophysiology of diabetic nephropathy and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the presentation of diabetic nephropathy.</p></list-item><list-item><p>Describe the evaluation of a patient with diabetic nephropathy.</p></list-item><list-item><p>Summarize the treatment of diabetic nephropathy.</p></list-item><list-item><p>Outline modalities to improve care coordination among interprofessional team members in order to improve outcomes for patients affected by diabetic nephropathy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20445&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20445">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20445.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease (ESKD) in developed countries, including the United States.<xref ref-type="bibr" rid="article-20445.r1">[1]</xref>&#x000a0;It&#x000a0;is considered a microvascular&#x000a0;complication and occurs in both diabetes mellitus type 1 (T1DM) and diabetes mellitus type 2 (T2DM). The disorder presents with persistent albuminuria and a progressive decline in the glomerular filtration rate. There is substantial evidence that early treatment can delay or prevent the progression of the disorder.</p>
        <p>Reliable tests for diagnosis and monitoring include urine albuminuria and the estimated GFR (eGFR). Optimizing glycemia and reasonable blood pressure control are pivotal in halting the progression of DKD.<xref ref-type="bibr" rid="article-20445.r2">[2]</xref></p>
      </sec>
      <sec id="article-20445.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Thirty to 40 percent of patients with diabetes mellitus&#x000a0;(DM)develop diabetic nephropathy.<xref ref-type="bibr" rid="article-20445.r3">[3]</xref>&#x000a0;The exact cause of diabetic nephropathy remains unknown, but insulin resistance, genetics, hyperglycemia, and an autoimmune process may be the causes.</p>
      </sec>
      <sec id="article-20445.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>While patients with type 2 diabetes mellitus may present with albuminuria at the time the diabetes is detected, diabetic nephropathy develops in type 1 diabetes 15 to 20 years later. This difference is mainly because the precise onset of type 2 diabetes is difficult to discern. Structural and functional changes occur in the kidney on account of diabetes and result in proteinuria, hypertension, and progressive reduction of kidney function, which is the hallmark of diabetic&#x000a0;nephropathy.</p>
        <p>Certain racial groups like African Americans, Native Americans, and Mexican Americans are at high risk of developing diabetic nephropathy. Studies have noted familial clustering, hinting that genetics plays a part in the risk of developing nephropathy.</p>
      </sec>
      <sec id="article-20445.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Hyperglycemia leads to the production of reactive oxygen species and activation of pathways, including protein kinase C, polyol, hexosamine, and advanced glycation end products (AGE). A significant feature is marked inflammation manifested by an&#x000a0;increase in cytokines and chemokines, including IL-6, MCP-1, TGF-beta (transforming growth factor-beta), and VEGF (vascular endothelial growth factor), causing inflammation fibrosis and increased vascular permeability. A podocytopathy ensues, resulting in albuminuria.&#x000a0;The resulting systemic and intraglomerular hypertension results in proteinuria. Proteinuria causes epithelial-mesenchymal cell transformation leading to fibroblasts and chronic tubular injury.</p>
      </sec>
      <sec id="article-20445.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Kimmelstiel-Wilson nodules, glomerular basement membrane thickening, and glomerular sclerosis, inflammation are the common pathologies seen in diabetic&#x000a0;nephropathy.</p>
      </sec>
      <sec id="article-20445.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Increasing duration of DM, poor glycemic control, and uncontrolled hypertension are strong risk factors for the development of diabetic nephropathy (DN). A family history of hypertension and cardiovascular events in first-degree relatives is also a strong risk factor for developing diabetic nephropathy. Obesity, smoking, and hyperlipidemia are risk factors for DN. This, along with family clustering, suggests genetic factors could also be at play. Several genes, including polymorphisms in angiotensin-converting enzyme (ACE) and angiotensin receptor, are being studied. Males are at higher risk of developing diabetic nephropathy.</p>
        <p>Diabetic nephropathy is diagnosed&#x000a0;by persistent albuminuria on two or more occasions, separated at least by three months on early morning urine samples. Persistent albuminuria is greater than 300 mg over 24 hours or greater than 200 micrograms per minute.&#x000a0;Moderately increased albuminuria is when the urine albumin excretion rate is between 30 to 300 mg over 24 hours and is a marker of early DN. It is critical to exclude a urinary tract infection as the cause of albuminuria by a urinalysis.&#x000a0;</p>
        <p>Early in the course of the&#x000a0;disease, patients are often asymptomatic and are diagnosed&#x000a0;during screening with levels of 30 to 300 mg/g creatinine. Once nephropathy sets in, patients present&#x000a0;with fatigue, foamy urine (urine protein greater than 3.5 g per day), and pedal edema due to hypoalbuminemia and nephrotic syndrome. They may also have associated peripheral vascular disease, hypertension, coronary artery disease, and diabetic retinopathy.</p>
      </sec>
      <sec id="article-20445.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Proteinuria is the hallmark of diabetic nephropathy. The&#x000a0;absence of retinopathy makes diabetic nephropathy less likely in T1DM.</p>
        <p>The scenario is more difficult in T2DM than with&#x000a0;T1DM. The exact time of the onset of&#x000a0;T2DM is unclear in most patients.&#x000a0;History and physical exam play a crucial role in diagnosing diabetic nephropathy in T2DM.</p>
        <p>The criteria for diagnosis include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Elevated blood pressure</p>
          </list-item>
          <list-item>
            <p>Progressive decline in glomerular filtration rate (GFR)</p>
          </list-item>
          <list-item>
            <p>Persistent albuminuria (greater than 300 mg/d) on at least two visits 3-6 months apart.&#x000a0;</p>
          </list-item>
        </list>
        <p>Urine analysis is used to quantify urea, creatinine, and protein. Microscopy is done to rule out a nephritic cause. Serum and urine electrophoresis is done to rule out multiple myeloma, and renal ultrasound is done to assess the kidney size. A renal biopsy is done when the diagnosis is not clear.</p>
      </sec>
      <sec id="article-20445.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of diabetic nephropathy targets four areas: cardiovascular risk reduction, glycemic control, control of blood pressure, and inhibition of the renin-angiotensin system (RAS).</p>
        <p>Risk-factor modification, including tobacco cessation and optimal lipid control&#x000a0;strategies, are crucial for cardiovascular risk reduction.</p>
        <p>Studies have shown a significant reduction in the risk of developing proteinuria and microalbuminuria with intensive diabetes control in T1DM.<xref ref-type="bibr" rid="article-20445.r4">[4]</xref>&#x000a0;These studies include DCCT (Diabetes Control and Complications Trial) and EDIC (Epidemiology of Diabetes Interventions and Complications study). The benefits of good glycemic control early in the onset of disease carried over even after a long time, despite glycemic control being similar in both groups on longer follow up. This effect is "metabolic memory," a term coined by DCCT/EDIC investigators.</p>
        <p>In T2DM, UKPDS (United Kingdom Prospective Diabetes Study) showed that targeting an HbA1C of 7% led to a lower risk of microvascular complications, including nephropathy.<xref ref-type="bibr" rid="article-20445.r5">[5]</xref>&#x000a0;However, blood pressure (BP) control also led to a decrease in cardiovascular mortality.</p>
        <p>Studies have shown the benefit of ARBs (angiotensin receptor blockers) in delaying the progression of kidney disease.<xref ref-type="bibr" rid="article-20445.r6">[6]</xref><xref ref-type="bibr" rid="article-20445.r7">[7]</xref>&#x000a0;These include studies like RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan Study)&#x000a0;and IDNT (Irbesartan Diabetes Nephropathy Trial), which also showed that the BP achieved, better-predicted kidney outcome rather than BP at entry, emphasizing the need for BP control. UKPDS showed the benefit of BP control on any DM-related complication such as death, adverse cardiovascular events, and the composite of microvascular events. However, aggressive control of systolic BP to less than 120 mm Hg, as opposed to standard therapy (less than 140 mm Hg systolic), found no difference in cardiovascular outcome or end-stage renal disease. The Eighth Joint National Committee (JNC 8) guidelines recommend a goal BP less than 140/90 mm Hg for most patients with&#x000a0;T2DM&#x000a0;and diabetic nephropathy, but with individualization.<xref ref-type="bibr" rid="article-20445.r8">[8]</xref>&#x000a0;Recent diabetic society guidelines suggest goals of 130/80 for people with diabetes.</p>
        <p>While RAS blockade is crucial to prevent the development of diabetic nephropathy, multiple studies show that early therapy in patients with&#x000a0;T1DM&#x000a0;is ineffective in preventing the development of microalbuminuria. However, studies, including ROADMAP (Randomized Olmesartan and Diabetes Microalbuminuria Prevention), have shown that RAS blockade can prevent the development of microalbuminuria in&#x000a0;T2DM.<xref ref-type="bibr" rid="article-20445.r9">[9]</xref></p>
        <p>Studies like IRMA2 (Irbesartan in Microalbuminuria, Type 2 Diabetic Nephropathy Trial)&#x000a0;have shown the benefit of ARB in preventing proteinuria in patients with microalbuminuria.<xref ref-type="bibr" rid="article-20445.r10">[10]</xref>&#x000a0;Studies in patients with&#x000a0;T1DM&#x000a0;and overt proteinuria have also shown that ACE inhibitors slow the progress of diabetic nephropathy. The IDNT and RENAAL studies have shown similar benefits in&#x000a0;T2DM&#x000a0;patients. These studies provide clear evidence of the benefit of RAS-blocking medication on slowing progression of diabetic nephropathy, independent of their effect on BP. However, the use of more than&#x000a0;one RAS-blocking agents resulted in&#x000a0;multiple adverse outcomes, including acute renal failure, and has&#x000a0;fallen out of favor.</p>
        <p>Newer drugs like a third-generation mineralocorticoid receptor antagonist,&#x000a0;finerenone, has shown albuminuria reduction in diabetic nephropathy at 90 days, on patients already on ARB.<xref ref-type="bibr" rid="article-20445.r11">[11]</xref>&#x000a0;The EMPAREG and CANVAS studies showed that&#x000a0;SGLT2 (sodium-glucose co-transporter 2) inhibitors that prevent reabsorption of glucose via the renal tubules reduced cardiovascular mortality.<xref ref-type="bibr" rid="article-20445.r12">[12]</xref>&#x000a0;In these cardiovascular outcome trials, the SGLT2 inhibitors had positive effects on kidney outcomes, namely albuminuria reduction and a reduction in the occurrence of a composite renal outcome. However, since these are secondary outcomes of trials designed to test cardiovascular benefit, many studies are now underway to test the actual potential of this group of drugs to prevent the progression of diabetic nephropathy.</p>
        <p>
<bold>Renal Replacement</bold>
</p>
        <p>Once the end-stage renal disease develops with a GFR of 10-15 ml/min, renal replacement therapy may be required. There are several options for dialysis, including peritoneal, hemodialysis, and renal transplant. Renal transplant is considered the best option, and this alternative must be discussed early with the family.</p>
      </sec>
      <sec id="article-20445.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Multiple myeloma</p>
          </list-item>
          <list-item>
            <p>Nephrotic syndrome</p>
          </list-item>
          <list-item>
            <p>Renal artery stenosis</p>
          </list-item>
          <list-item>
            <p>Tubulointerstitial nephritis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20445.s11" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>
<bold>Effect of CKD on Diabetes Drugs</bold>
</p>
        <p>The kidneys play a crucial role in clearing insulin from the body.&#x000a0; When the kidney fails, insulin remains for longer periods in the body, and this warrants dose reduction of insulin to prevent hypoglycemia. This principle also is true for most oral antidiabetic medications that are cleared from the kidney.</p>
        <p>Metformin is contraindicated in patients with eGFR less than 30 mL/min/1.73 m2, due to the likelihood of lactic acidosis. With most oral drugs, the physician needs to be cautious when the eGFR is less than 45 mL per minute and especially below 30 mL per minute.</p>
        <p>Patients with diabetic nephropathy are at risk of developing acute&#x000a0;kidney injury (AKI) and, one must exercise extreme caution with the use of nephrotoxic medications like NSAID, intravenous contrast, among others.</p>
      </sec>
      <sec id="article-20445.s12" sec-type="Staging">
        <title>Staging</title>
        <p>
<bold>Current Guidelines</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Optimize blood glucose control</p>
          </list-item>
          <list-item>
            <p>Optimize blood pressure control with ACE inhibitors or ARBs</p>
          </list-item>
          <list-item>
            <p>Limit protein intake to 0.8 g/kg body weight</p>
          </list-item>
          <list-item>
            <p>Monitor serum creatinine and BUN</p>
          </list-item>
          <list-item>
            <p>Monitor urine albumin - creatinine ratio</p>
          </list-item>
          <list-item>
            <p>ACE inhibitors or ARB are not recommended in patients with normal BP, normal GFR and normal urinary albumin to creatinine ratio</p>
          </list-item>
          <list-item>
            <p>when GFR falls below 60 ml/min, assess for complications of chronic kidney disease</p>
          </list-item>
          <list-item>
            <p>If GFR is below 30 ml/min, refer to a nephrologist for renal replacement</p>
          </list-item>
          <list-item>
            <p>Always refer to a nephrologist to manage chronic kidney disease</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20445.s13" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Diabetic nephropathy carries high morbidity and mortality. Microalbuminuria is an independent risk factor for cardiovascular mortality. The majority of patients die from end-stage renal disease. In addition, diabetic retinopathy is associated with diabetic nephropathy.</p>
      </sec>
      <sec id="article-20445.s14" sec-type="Consultations">
        <title>Consultations</title>
        <p>When the eGFR is below 45 mL per minute, and the patient has albuminuria greater than 300 mg/g creatinine a nephrology consult is prudent to establish a baseline for future renal replacement therapy.</p>
      </sec>
      <sec id="article-20445.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <list list-type="bullet">
          <list-item>
            <p>Protein intake should be around 0.8 g&#x000a0;per kilogram body weight.</p>
          </list-item>
          <list-item>
            <p>Hemoglobin A1c should be less than 7.5%</p>
          </list-item>
          <list-item>
            <p>Blood pressure should be less than 120/80 mmHg</p>
          </list-item>
          <list-item>
            <p>Avoid nephrotoxic agents and drugs</p>
          </list-item>
          <list-item>
            <p>Check urine for albumin regularly</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20445.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Diabetic nephropathy is a serious disorder with life long repercussions and a high mortality rate. There is no cure for the disorder, and all treatments have limitations. The key today is to prevent nephropathy from developing. Thus an interprofessional clinical team is crucial in reducing cardiovascular risk factors, glycemic control, and decreased risk of complications across multiple countries <xref ref-type="bibr" rid="article-20445.r13">[13]</xref>.</p>
        <p>[Level 5]</p>
        <p>The&#x000a0;current recommendation is that the patient&#x000a0;also is included as a member of this interprofessional treatment team for optimal outcomes. The nurse should educate the patient on the importance of glucose control, exercise, follow up, and a healthy diet, whereas the pharmacist should educate the patient on medication compliance and blood pressure control. A dietary consult should be made to educate the patient on low protein foods, and a social worker should ensure that the patient has the support and financial resources for treatment. The nephrologist and dialysis nurses should educate the patient on renal replacement options, and the transplant nurse should educate the patient on the indications and benefits of a transplant.</p>
        <p>Further, these patients should be taught how to monitor and treat their blood glucose levels at home. Studies show that patients who remain compliant with home monitoring of blood glucose tend to&#x000a0;have a delay in renal dysfunction.<xref ref-type="bibr" rid="article-20445.r14">[14]</xref></p>
        <p>Evidence shows that working in an interprofessional team with open communication offers patients the best outcomes.&#x000a0;<xref ref-type="bibr" rid="article-20445.r15">[15]</xref></p>
      </sec>
      <sec id="article-20445.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20445&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20445">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/diabetes/diabetic-nephropathy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=20445">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20445/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20445">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20445.s18">
        <title>References</title>
        <ref id="article-20445.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rabkin</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Diabetic nephropathy.</article-title>
            <source>Clin Cornerstone</source>
            <year>2003</year>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>1</fpage>
            <page-range>1-11</page-range>
            <pub-id pub-id-type="pmid">12800476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20445.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Diabetes Canada Clinical Practice Guidelines Expert Committee</collab>
              <name>
                <surname>McFarlane</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cherney</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Senior</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Chronic Kidney Disease in Diabetes.</article-title>
            <source>Can J Diabetes</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>42 Suppl 1</volume>
            <fpage>S201</fpage>
            <page-range>S201-S209</page-range>
            <pub-id pub-id-type="pmid">29650098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20445.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Umanath</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Update on Diabetic Nephropathy: Core Curriculum 2018.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>884</fpage>
            <page-range>884-895</page-range>
            <pub-id pub-id-type="pmid">29398179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20445.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <collab>DCCT/EDIC research group</collab>
            <article-title>Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>2</volume>
            <issue>10</issue>
            <fpage>793</fpage>
            <page-range>793-800</page-range>
            <pub-id pub-id-type="pmid">25043685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20445.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Genuth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eastman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lachin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lebovitz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nathan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vinicor</surname>
                <given-names>F</given-names>
              </name>
              <collab>American Diabetes Association</collab>
            </person-group>
            <article-title>Implications of the United kingdom prospective diabetes study.</article-title>
            <source>Diabetes Care</source>
            <year>2003</year>
            <month>Jan</month>
            <volume>26 Suppl 1</volume>
            <fpage>S28</fpage>
            <page-range>S28-32</page-range>
            <pub-id pub-id-type="pmid">12502617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20445.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brenner</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>de Zeeuw</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Keane</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Mitch</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Parving</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Remuzzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Snapinn</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Shahinfar</surname>
                <given-names>S</given-names>
              </name>
              <collab>RENAAL Study Investigators</collab>
            </person-group>
            <article-title>Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.</article-title>
            <source>N Engl J Med</source>
            <year>2001</year>
            <month>Sep</month>
            <day>20</day>
            <volume>345</volume>
            <issue>12</issue>
            <fpage>861</fpage>
            <page-range>861-9</page-range>
            <pub-id pub-id-type="pmid">11565518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20445.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Hunsicker</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Berl</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pohl</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Ritz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Rohde</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Raz</surname>
                <given-names>I</given-names>
              </name>
              <collab>Collaborative Study Group</collab>
            </person-group>
            <article-title>Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2001</year>
            <month>Sep</month>
            <day>20</day>
            <volume>345</volume>
            <issue>12</issue>
            <fpage>851</fpage>
            <page-range>851-60</page-range>
            <pub-id pub-id-type="pmid">11565517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20445.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armstrong</surname>
                <given-names>C</given-names>
              </name>
              <collab>Joint National Committee</collab>
            </person-group>
            <article-title>JNC8 guidelines for the management of hypertension in adults.</article-title>
            <source>Am Fam Physician</source>
            <year>2014</year>
            <month>Oct</month>
            <day>01</day>
            <volume>90</volume>
            <issue>7</issue>
            <fpage>503</fpage>
            <page-range>503-4</page-range>
            <pub-id pub-id-type="pmid">25369633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20445.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Menne</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ritz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ruilope</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Chatzikyrkou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Viberti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Haller</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2014</year>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>e000810</fpage>
            <pub-id pub-id-type="pmid">24772521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20445.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parving</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Lehnert</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Br&#x000f6;chner-Mortensen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gomis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arner</surname>
                <given-names>P</given-names>
              </name>
              <collab>Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group</collab>
            </person-group>
            <article-title>The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2001</year>
            <month>Sep</month>
            <day>20</day>
            <volume>345</volume>
            <issue>12</issue>
            <fpage>870</fpage>
            <page-range>870-8</page-range>
            <pub-id pub-id-type="pmid">11565519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20445.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bakris</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Gansevoort</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Haller</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Remuzzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rossing</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schmieder</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Nowack</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kolkhof</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pieper</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kimmeskamp-Kirschbaum</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ruilope</surname>
                <given-names>LM</given-names>
              </name>
              <collab>Mineralocorticoid Receptor Antagonist Tolerability Study&#x02013;Diabetic Nephropathy (ARTS-DN) Study Group</collab>
            </person-group>
            <article-title>Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2015</year>
            <month>Sep</month>
            <day>01</day>
            <volume>314</volume>
            <issue>9</issue>
            <fpage>884</fpage>
            <page-range>884-94</page-range>
            <pub-id pub-id-type="pmid">26325557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20445.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rastogi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhansali</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review.</article-title>
            <source>Diabetes Ther</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>1245</fpage>
            <page-range>1245-1251</page-range>
            <pub-id pub-id-type="pmid">29076040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20445.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McGill</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blonde</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>JCN</given-names>
              </name>
              <name>
                <surname>Khunti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lavalle</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>CJ</given-names>
              </name>
              <collab>Global Partnership for Effective Diabetes Management</collab>
            </person-group>
            <article-title>The interdisciplinary team in type 2 diabetes management: Challenges and best practice solutions from real-world scenarios.</article-title>
            <source>J Clin Transl Endocrinol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>7</volume>
            <fpage>21</fpage>
            <page-range>21-27</page-range>
            <pub-id pub-id-type="pmid">29067246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20445.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahnensmith</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Zorzanello</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>A quality improvement model for optimizing care of the diabetic end-stage renal disease patient.</article-title>
            <source>Semin Dial</source>
            <year>2010</year>
            <season>Mar-Apr</season>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>206</fpage>
            <page-range>206-13</page-range>
            <pub-id pub-id-type="pmid">20525109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20445.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shen</surname>
                <given-names>ZZ</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Early short-term intensive multidisciplinary diabetes care: A ten-year follow-up of outcomes.</article-title>
            <source>Diabetes Res Clin Pract</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>130</volume>
            <fpage>133</fpage>
            <page-range>133-141</page-range>
            <pub-id pub-id-type="pmid">28618325</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
